The 2012 Access to Medicine Index was published on November 28th, 2012. The report evaluates the top 20 pharmaceutical companies’ access to medicine activities.
GlaxoSmithKline is again at the head of the Index. It is the leader in general access to medicine management, research and development activity, capability advancement and drug donation and philanthropy. It makes its entire vaccine portfolio available to developing countries at an equitable price. It has a pro-access approach to patents and licencing. Although it has a code of conduct for ethical marketing that exceeds the basic minimum standards, it is still not fully transparent about its product registration processes. It does not routinely undertake technology transfer, except for vaccines.